Skip to main content
Sexually Transmitted Infections logoLink to Sexually Transmitted Infections
. 2006 Dec;82(Suppl 4):iv28–iv30. doi: 10.1136/sti.2006.023168

Vulvovaginal candidiasis

D J White 1, A Vanthuyne 1
PMCID: PMC2563903  PMID: 17151050

Vulvovaginal candidiasis (VVC) is a syndrome rather than an infection and diagnosis of VVC does not rely on laboratory or clinical criteria alone but a combination of the two. The disease spectrum ranges from “innocent bystander,” where symptoms are wrongly attributed to coincidental isolation of candida to complicated disease where VVC is severe, persistent, or recurrent or there is an underlying host abnormality.1

Who to test and treat?

Screening is not required for asymptomatic women (evidence level IV, recommendation grade C).2,3

Episodic VVC

Episodic VVC includes normal women with mild to moderate symptoms and no history of persistent or recurrent symptoms1 (evidence level IV, recommendation grade C).

Symptoms suggestive of episodic VVC include external dysuria, vulval pruritus, swelling, or redness. Signs include vulval oedema, fissures, excoriation, or thick curdy discharge. The vaginal pH is usually normal4,5,6,7,8,9 (evidence level III, recommendation grade B).

  • Testing is recommended for episodic VVC whenever possible (evidence level III, recommendation grade B).4,5,6,7,8,9

  • Treatment is clearly indicated for symptomatic women who are microscopy positive and/or those who are culture positive4,5,6,7,8,9 (evidence level III, recommendation grade B).

  • Treatment on the basis of symptoms alone is common clinical practice but results in the overtreatment of a large number of women4,5,6,7,8,9 (evidence level III, recommendation grade B).

Complicated VVC

This includes severe episodic VVC, persistent non‐Candida albicans infection, recurrent VVC, and those with underlying host abnormality—for example, pregnancy, HIV infection and diabetes1 (evidence level IV, recommendation grade C).

As well as microbiological testing women with chronic symptoms need a careful history and examination. Particular attention needs to be paid to alternative diagnoses, most commonly vulval eczema/dermatitis. Possibilities otherwise include other causes of vaginal discharge—for example, recurrent bacterial vaginosis and also recurrent herpes, vulval vestibulitis syndrome, and other vulvar dermatoses10 (evidence level III, recommendation grade B). More than one condition may occur and this may vary with time—for example, the patient may cycle between bacterial vaginosis and VVC.11 A general examination of the skin can sometimes be very helpful (evidence level IV, recommendation grade C).

Recommended tests

Except in research settings samples are almost universally taken with a cotton tipped swab from the vaginal wall.

Possible uncomplicated VVC

In the context of specialist services offering a comprehensive sexual health service routine microscopy and culture is the standard of care for symptomatic women4,5,6,7,8,9 (evidence level III, recommendation grade B).

A vaginal swab taken from the anterior fornix12 (evidence level III, recommendation grade B).

  • Gram or wet film examination4,5,6,7,8,9 (evidence level III, recommendation grade B)

  • Directly plated to solid fungal media. Speciation to albicans/non‐albicans is strongly preferred3,13,14,15 (evidence level III, recommendation grade B).

  • Vaginal pH is not useful in the diagnosis of VVC which can coincide with bacterial vaginitis11 (evidence level IV, recommendation grade C).

Blind16 (evidence level III, recommendation grade B) or self taken swabs (evidence level IV, recommendation grade C) may be useful if directly taken swabs are not easily taken and if examination is not deemed necessary.

Complicated disease

Tests for individual episodes as above.

  • Speciation to albicans/non‐albicans is essential and should be performed to species level if a non‐albicans species is isolated on more than one occasion3,13,14,15 (evidence level III, recommendation grade B).

  • Self taken swabs are useful in obtaining culture evidence of recurrent/persistent VVC. These can taken when the patient is symptomatic before treatment and can be combined with a symptom diary as part of the assessment process (evidence level IV, recommendation grade C).

Recommended sites for testing

  • If a speculum is being passed then a cotton tipped swab should be used to take a sample from the anterior fornix12 (evidence level III, recommendation grade B).

  • If speculum is not being passed then blind16 (evidence level III, recommendation grade B) or self taken swabs may be used (evidence level IV, recommendation grade C)

Processing of samples

Microscopy should be of either a Gram stained or wet mount preparation4,5,6,7,8,9 (evidence level III, recommendation grade B). Culture should be from a directly plated solid fungal media (evidence level III, recommendation grade B). Chromogenic agar if available enables easy identification of species and mixed species infection and is preferred for investigation for complicated VVC17 (evidence level III, recommendation grade B).

Liquid culture media are not recommended as they do not allow semi‐quantitation. Other methods of testing for candida such as latex agglutination have not made their way into routine clinical practice.18,19,20 Polymerase chain reaction is currently of use only as a research tool.21,22,23

Antifungal sensitivities

There is no proved utility of antifungal sensitivity testing for complicated VVC24 (evidence level III, recommendation grade B). It is possibly indicated for women with a chronic immunological abnormality25 (evidence level III, recommendation grade B); or repeated isolation of a non‐albicans yeast26,27 (evidence level IV, recommendation grade C).

Reporting of results

Microscopy should be reported as fungal pseudohyphae and/or blastospores present or absent4,5,6,7,8,9 (evidence level III, recommendation grade B).

Cultures should be reported as3,13,14,15 (evidence level III, recommendation grade B):

  • Negative

  • Light growth <10 colonies per plate

  • Moderate growth 10–99 colonies per plate

  • Heavy growth ⩾100 colonies per plate.

Interpretation of results

In interpreting results the possibility of candida being an “innocent bystander” needs to be considered—that is, that symptoms from another condition are wrongly attributed to coincidental asymptomatic isolation of candida1 (evidence level IV, recommendation grade C).

Isolation of candida is common in asymptomatic women.2,3 Treatment is not indicated in the absence of symptoms (evidence level III, recommendation grade B).

Symptoms correlate with hyphal burden, and the presence of pseudohyphae and/or blastospores on light microscopy implies a relatively high fungal burden.3,13,14,15 Microscopy is therefore relatively specific but insensitive in the diagnosis of VVC4,5,6,7,8,9,28,29 (evidence level III, recommendation grade B). In contrast, culture is sensitive but not specific. Symptoms are not clearly associated with colony counts of <10 colonies/plate (evidence level III, recommendation grade B).

Severity of individual episodes is based on clinical and not laboratory data. Severe disease may however require more intensive treatment30 (evidence level Ib, recommendation grade A).

Non‐albicans species, most commonly C glabrata, are isolated in 5–10% of episodic VVC but cannot be distinguished from C albicans on clinical criteria10,26,31 (evidence level III, recommendation grade B). They are inherently relatively azole resistant and may not respond well to conventional courses of antifungal treatment10,26 (evidence level III, recommendation grade B).

Recurrent VVC is defined as four or more attacks of VVC in a year1 (evidence level IV, recommendation grade C). It is usually caused by C albicans. Although there is evidence of persistence of infection between attacks using PCR (so called vaginal relapse) culture is negative between attacks. A diagnosis of recurrent VVC therefore requires either positive microscopy or a moderate/heavy growth of C albicans, when symptomatic, on at least two occasions with treatment and at least partial resolution of symptoms in between (evidence level IV, recommendation grade C).

Persistent VVC is usually caused by non‐C albicans yeast.1 Risk factors include underlying host abnormality and being peri‐menopausal. Diagnosis of persistent/chronic non‐albicans infection requires isolation of the same species of yeast on at least two concurrent samples and treatment on the first occasion (evidence level IV, recommendation grade C).

Recommendation for test of cure

Tests of cure are only indicated after the treatment of persistent non‐albicans infection (evidence level IV, recommendation grade C). Proof of cure requires at least two negative cultures at least a week after treatment and with an interval of at least a week between cultures (evidence level IV, recommendation grade C).

Stakeholder involvement

No stakeholders were involved in developing the guideline.

Rigour of development

The Cochrane database was searched for articles on expressions “Candidiasis”, “Vulvovaginal”. Medline (1966–Jan 2003) was searched using expressions “Candidiasis”, “Vulvovaginal/di” [Diagnosis] and “Candidiasis”, “Vulvovaginal” (1990–Jan 2003). The resulting articles were hand searched and sorted. Further references were obtained from these articles. References were also obtained from Candida and Candidosis, A Review and Bibliography by Odds.2 This book contains an extensive bibliography for papers predating 1988.

Applicability

The diagnosis of VVC is syndromic. Diagnostic criteria may therefore vary with the clinical setting. These guidelines are specifically written for women of reproductive age presenting to departments of genitourinary medicine or sexual health. They are written on the assumption that on‐site facilities are available for microscopy with direct inoculation of culture media and incubation of microbiological samples.

In other settings the effects of transportation and the use of transport media have not been investigated but it is likely that germination and growth will occur32 thereby increasing the sensitivity and reducing specificity. If transport media are used then slides for microscopy should be prepared before inoculation.

Auditable outcome measures

  • Proportion of symptomatic culture positive women (moderate or heavy growth) who are microscopy positive. Target: 50%

  • Proportion of women with complicated VVC who have speciation performed. Target 100%

  • Proportion of women dispensed antifungals with negative culture results. Target less than 30%.

Abbreviations

VVC - vulvovaginal candidiasis

Footnotes

Conflict of interest: AV as no conflicts of interest. DJW has received a research grant from Astra Zeneca.

References

  • 1.Sobel J D, Faro S, Force R W.et al Vulvovaginal candidiasis: epidemiologic, diagnostic, and therapeutic considerations. Am J Obstet Gynecol 1998178203–211. [DOI] [PubMed] [Google Scholar]
  • 2.Odds F C. In: Candida and candidosis; a review and bibliography. 2nd ed. London: Bailliere Tindall, 1988
  • 3.Priestley C J, Jones B M, Dhar J.et al What is normal vaginal flora? Genitourin Med 19977323–28. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Zdolsek B, Hellberg D, Froman G.et al Culture and wet smear microscopy in the diagnosis of low‐symptomatic vulvovaginal candidosis. Eur J Obstet Gynecol Reproduct Biol 19955847–51. [DOI] [PubMed] [Google Scholar]
  • 5.Sonnex C, Lefort W. Microscopic features of vaginal candidiasis and their relation to symptomatology. Sex Transm Infect 199975417–419. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Schaaf V M, Perez‐Stable E J, Borchardt K. The limited value of symptoms and signs in the diagnosis of vaginal infections. Arch Intern Med 19901501929–1933. [PubMed] [Google Scholar]
  • 7.Eckert L O, Hawes S E, Stevens C E.et al Vulvovaginal candidiasis: clinical manifestations, risk factors, management algorithm. Obstet Gynecol 199892757–765. [DOI] [PubMed] [Google Scholar]
  • 8.Bergman J J, Berg A O, Schneeweiss R.et al Clinical comparison of microscopic and culture techniques in the diagnosis of Candida vaginitis. J Fam Pract 198418549–552. [PubMed] [Google Scholar]
  • 9.Abbott J. Clinical and microscopic diagnosis of vaginal yeast infection: a prospective analysis. Ann Emerg Med 199525587–591. [DOI] [PubMed] [Google Scholar]
  • 10.Geiger A M, Foxman B, Sobel J D. Chronic vulvovaginal candidiasis: characteristics of women with Candida albicans, C glabrata, and no candida. Genitourin Med 199571304–307. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Hay P E, Ugwumadu A, Chowns J. Sex, thrush and bacterial vaginosis. Int J STD AIDS 19978603–608. [DOI] [PubMed] [Google Scholar]
  • 12.Emmerson J, Gunputrao A, Hawkswell J.et al Sampling for vaginal candidosis: how good is it? Int J STD AIDS 19945356–358. [PubMed] [Google Scholar]
  • 13.Hopwood V, Crowley T, Horrocks C T.et al Vaginal candidosis: relation between yeast counts and symptoms and clinical signs in non‐pregnant women. Genitourin Med 198864331–334. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Odds F C, Webster C E, Riley V C.et al Epidemiology of vaginal Candida infection: significance of numbers of vaginal yeasts and their biotypes. Eur J Obstet Gynecol Reprod Biol 19872553–66. [DOI] [PubMed] [Google Scholar]
  • 15.Odds F C, Webster C E, Mayuranathan P.et al Candida concentrations in the vagina and their association with signs and symptoms of vaginal candidosis. J Med Vet Mycol 198826277–283. [DOI] [PubMed] [Google Scholar]
  • 16.Blake D R, Duggan A, Quinn T.et al Evaluation of vaginal infections in adolescent women: can it be done without a speculum? Pediatrics 1998102(4 Pt 1)939–944. [DOI] [PubMed] [Google Scholar]
  • 17.Houang E T, Chu K C, Koehler A P.et al Use of CHROMagar Candida for genital specimens in the diagnostic laboratory. J Clinl Pathol 199750563–565. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Brown H L, Fuller D A, Davis T E.et al Evaluation of the Affirm ambient temperature transport system for the detection and identification of Trichomonas vaginalis, Gardnerella vaginalis, and Candida species from vaginal fluid specimens. J Clin Microbiol 2001393197–3199. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Evans E G, Lacey C J, Carney J A. Criteria for the diagnosis of vaginal candidosis: evaluation of a new latex agglutination test. Eur J Obstet Gynecol Reprod Biol 198622365–371. [DOI] [PubMed] [Google Scholar]
  • 20.Lewis D H. Use of slide latex agglutination test for rapid diagnosis of vaginal candidosis. Genitourin Med 198864136. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Giraldo P, von Nowaskonski A, Gomes F A.et al Vaginal colonization by Candida in asymptomatic women with and without a history of recurrent vulvovaginal candidiasis. Obstet Gynecol 200095413–416. [DOI] [PubMed] [Google Scholar]
  • 22.Weissenbacher S, Witkin S S, Tolbert V.et al Value of Candida polymerase chain reaction and vaginal cytokine analysis for the differential diagnosis of women with recurrent vulvovaginitis. Infect Dis Obstet Gynecol 20008244–247. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.El‐Din S S, Reynolds M T, Ashbee H R.et al An investigation into the pathogenesis of vulvo‐vaginal candidosis. Sex Transm Infect 200177179–183. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Sobel J D, Zervos M, Reed B D.et al Fluconazole susceptibility of vaginal isolates obtained from women with complicated Candida vaginitis: clinical implications. Antimicrob Agents Chemother 20034734–38. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Vazquez J A, Sobel J D, Peng G.et al Evolution of vaginal Candida species recovered from human immunodeficiency virus‐infected women receiving fluconazole prophylaxis: the emergence of Candida glabrata? Terry Beirn Community Programs for Clinical Research in AIDS (CPCRA). Clin Infect Dis 1999281025–1031. [DOI] [PubMed] [Google Scholar]
  • 26.Nyirjesy P, Seeney S M, Grody M H.et al Chronic fungal vaginitis: the value of cultures. Am J Obstet Gynecol 1995173(3 Pt 1)820–823. [DOI] [PubMed] [Google Scholar]
  • 27.Otero L, Fleites A, Mendez F J.et al Susceptibility of Candida species isolated from female prostitutes with vulvovaginitis to antifungal agents and boric acid. Eur J Obstet Gynecol Reprod Biol 19991859–61. [DOI] [PubMed] [Google Scholar]
  • 28.Schaaf V M, Perez‐Stable E J, Borchardt K. The limited value of symptoms and signs in the diagnosis of vaginal infections. Arch Intern Med 19901501929–1933. [PubMed] [Google Scholar]
  • 29.Sonnex C, Lefort W. Microscopic features of vaginal candidiasis and their relation to symptomatology. Sex Transm Infect 199975417–419. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Sobel J D, Kapernick P S, Zervos M.et al Treatment of complicated Candida vaginitis: comparison of single and sequential doses of fluconazole. Am J Obstet Gynecol 2001185363–369. [DOI] [PubMed] [Google Scholar]
  • 31.Geiger A M, Foxman B, Sobel J D. Chronic vulvovaginal candidiasis: characteristics of women with Candida albicans, C glabrata and no candida. Genitourin Med 199571304–307. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Cibley L J, Cibley L J, Baldwin D. Diagnosing candidiasis. A new, cost‐effective technique. J Reprod Med 199843925–928. [PubMed] [Google Scholar]

Articles from Sexually Transmitted Infections are provided here courtesy of BMJ Publishing Group

RESOURCES